Fluzone High-Dose was 24.2% more effective in preventing influenza in adults aged 65 years or older than regular Fluzone in a large-scale clinical trial, vaccine maker Sanofi Pasteur told the Advisory ...

SWIFTWATER, Pa. — Sanofi Pasteur, the vaccines division of Sanofi, released data from a new study examining the ability of its Fluzone High-Dose vaccine to provoke an immune response in elderly and ...

Because older people have a weaker immune response to influenza vaccine than younger people do and are at increased risk for hospitalization and death from flu, the Food and Drug Administration ...

While the flu vaccine is the best way to prepare for flu season, older adults don't have as robust an immune response to the jab as young people do. To address this problem, Sanofi Pasteur formulated ...

Not all flu shots are created equal. That's the message Sanofi wants to convey as it pushes the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP) to ...

When making vaccine decisions with their patients, healthcare providers (HCPs) rely on treatment guidance from the Centers for Disease Control and Prevention (CDC). They trust the agency to review the ...

Fluzone High-Dose Quadrivalent is a vaccine. This vaccine is recommended to help protect against influenza (flu) and associated pneumonia in persons aged 60 years and older. For more information, see ...

Compared to standard-dose influenza vaccines, Efluelda/Fluzone High-Dose demonstrated a reduction in laboratory-confirmed influenza hospitalizations by an additional 31.9% (95% CI, 19.7 to 42.2; ...

The FDA has approved Sanofi’s licensure request for vaccine approval for the upcoming 2022-2023 flu season, which would include Fluzone High-Dose Quadrivalent (influenza vaccine), Flublok Quadrivalent ...

BRIDGEWATER, N.J., March 14, 2025 /PRNewswire/ -- Sanofi announced today the immediate adoption of influenza strains selected by the US Food and Drug Administration (FDA) to advance the manufacturing ...

Dec 10 (Reuters) - Moderna Inc (MRNA.O), opens new tab executives called on investors to wait for more data amid a sharp selloff in its shares on Friday, after early data showed its mRNA-based flu ...